President Biden and Senate Democrats have been putting pressure on Big Pharma to cap insulin for all patients at $35 for more than a year now (as Republican blocked that measure in Congress) but today drugmaker Eli Lilly announced they will do just that.
Eli Lilly will cap the out-of-pocket cost of its insulin at $35 a month, the drugmaker said Wednesday. The move, experts say, could prompt other insulin makers in the U.S. to follow suit.
The change, which Eli Lilly said takes effect immediately, puts the drugmaker in line with a provision in the Inflation Reduction Act, which in January imposed a $35 monthly cap on the out-of-pocket cost of insulin for seniors enrolled in Medicare.
President Joe Biden praised the move in a tweet, calling on other drugmakers to also lower insulin prices. Biden made insulin costs a focus of his State of the Union speech last month.
The American Diabetes Association also applauded the decision, and encouraged other insulin manufacturers to lower costs.
Insulin makers have faced pressure from members of Congress and advocacy groups to lower the cost of the lifesaving medication. Insulin costs in the U.S. are notoriously high compared to the costs in other countries; the Rand Corporation, a public policy think tank, estimated that in 2018, the average list price for one vial of insulin in the U.S. was $98.70.
"Patients should have a consistent and lower cost experience at the pharmacy counter," David Ricks, Eli Lilly’s CEO, said on a press call Wednesday.
The cap automatically applies to people with private insurance. People without insurance will be eligible as long as they sign up for Eli Lilly’s copay assistance program.
That program began providing insulin to patients — regardless of their insurance statuses — for no more than $35 a month in 2020 because of the pandemic.
The cap applies to all of Eli Lilly’s insulin products, said Kelly Smith, a spokesperson for the company. In addition to the cost caps, the company will lower the list price for several of its products, including Humalog, this year.
Ricks said that the decision came as a result of conversations between the company and members of Congress about the cost of the medication.
The passage of the Inflation Reduction Act resulted in a "split situation" in the U.S., he said, where seniors benefited from a $35 out-of-pocket monthly cap, but people with private insurance and the uninsured did not.